|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Braun DA, Hou Y, Bakouny Z, Ficial M,
Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA,
Elagina L, et al: Interplay of somatic alterations and immune
infiltration modulates response to PD-1 blockade in advanced clear
cell renal cell carcinoma. Nat Med. 26:909–918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maines F, Caffo O, Veccia A, Trentin C,
Tortora G, Galligioni E and Bria E: Sequencing new agents after
docetaxel in patients with metastatic castration-resistant prostate
cancer. Crit Rev Oncol Hematol. 96:498–506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choueiri TK, Fishman MN, Escudier B,
McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL,
McNeel DG, Curti B, et al: Immunomodulatory activity of nivolumab
in metastatic renal cell carcinoma. Clin Cancer Res. 22:5461–5471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abah MO, Ogenyi DO, Zhilenkova AV, Essogmo
FE, Ngaha Tchawe YS, Uchendu IK, Pascal AM, Nikitina NM, Rusanov
AS, Sanikovich VD, et al: Innovative therapies targeting
drug-resistant biomarkers in metastatic clear cell renal cell
carcinoma (ccRCC). Int J Mol Sci. 26:2652024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Linehan WM and Ricketts CJ: Decade in
review-kidney cancer: Discoveries, therapies and opportunities. Nat
Rev Urol. 11:614–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Praefcke GJK and McMahon HT: The dynamin
superfamily: Universal membrane tubulation and fission molecules?
Nat Rev Mol Cell Biol. 5:133–147. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vestal DJ: The guanylate-binding proteins
(GBPs): Proinflammatory cytokine-induced members of the dynamin
superfamily with unique GTPase activity. J Interferon Cytokine Res.
25:435–443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shenoy AR, Wellington DA, Kumar P, Kassa
H, Booth CJ, Cresswell P and MacMicking JD: GBP5 promotes NLRP3
inflammasome assembly and immunity in mammals. Science.
336:481–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tretina K, Park ES, Maminska A and
MacMicking JD: Interferon-induced guanylate-binding proteins:
Guardians of host defense in health and disease. J Exp Med.
216:482–500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fellenberg F, Hartmann TB, Dummer R,
Usener D, Schadendorf D and Eichmüller S: GBP-5 splicing variants:
New guanylate-binding proteins with tumor-associated expression and
antigenicity. J Invest Dermatol. 122:1510–1517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patil PA, Blakely AM, Lombardo KA, Machan
JT, Miner TJ, Wang LJ, Marwaha AS and Matoso A: Expression of
PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment
in gastric adenocarcinoma. Histopathology. 73:124–136. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao FY, Wang CH, Li X, Ma MZ, Tao GC, Yang
C, Li K, He XB, Tong SL, Zhao QC, et al: Guanylate binding protein
5 accelerates gastric cancer progression via the
JAK1-STAT1/GBP5/CXCL8 positive feedback loop. Am J Cancer Res.
13:1310–1328. 2023.PubMed/NCBI
|
|
16
|
Yu X, Jin J, Zheng Y, Zhu H, Xu H, Ma J,
Lan Q, Zhuang Z, Chen CC and Li M: GBP5 drives malignancy of
glioblastoma via the Src/ERK1/2/MMP3 pathway. Cell Death Dis.
12:2032021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng SW, Chen PC, Lin MH, Ger TR, Chiu HW
and Lin YF: GBP5 repression suppresses the metastatic potential and
PD-L1 expression in triple-negative breast cancer. Biomedicines.
9:3712021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng Z, Liu J, Yu YV and Jin YN: Machine
learning-based identification of an immunotherapy-related signature
to enhance outcomes and immunotherapy responses in melanoma. Front
Immunol. 15:14511032024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elsayed I, Elsayed N, Feng Q, Sheahan K,
Moran B and Wang X: Multi-OMICs data analysis identifies molecular
features correlating with tumor immunity in colon cancer. Cancer
Biomark. 33:261–271. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zou C, Shen J, Xu F, Ye Y, Wu Y and Xu S:
Immunoreactive microenvironment modulator GBP5 suppresses ovarian
cancer progression by inducing canonical pyroptosis. J Cancer.
15:3510–3530. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiang S, Li J, Shen J, Zhao Y, Wu X, Li M,
Yang X, Kaboli PJ, Du F, Zheng Y, et al: Identification of
prognostic genes in the tumor microenvironment of hepatocellular
carcinoma. Front Immunol. 12:6538362021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong Q, Li D, Yin Y, Cheng L and Ouyang S:
GBP5 expression predicted prognosis of immune checkpoint inhibitors
in small cell lung cancer and correlated with tumor immune
microenvironment. J Inflamm Res. 16:4153–4164. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiu HW, Lin CH, Lee HH, Lu HW, Lin YHK,
Lin YF and Lee HL: Guanylate binding protein 5 triggers NF-κB
activation to foster radioresistance, metastatic progression and
PD-L1 expression in oral squamous cell carcinoma. Clin Immunol.
259:1098922024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen HQ, Zhao J, Li Y, He LX, Huang YJ,
Shu WQ, Cao J, Liu WB and Liu JY: Gene expression network regulated
by DNA methylation and microRNA during microcystin-leucine arginine
induced malignant transformation in human hepatocyte L02 cells.
Toxicol Lett. 289:42–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitra A, Ghosh S, Porey S and Mal C: GBP5
and ACSS3: Two potential biomarkers of high-grade ovarian cancer
identified through downstream analysis of microarray data. J Biomol
Struct Dyn. 41:4601–4613. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi Z, Gu J, Yao Y and Wu Z:
Identification of a predictive gene signature related to pyroptosis
for the prognosis of cutaneous melanoma. Medicine (Baltimore).
101:e305642022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Diaz-Montero CM, Rini BI and Finke JH: The
immunology of renal cell carcinoma. Nat Rev Nephrol. 16:721–735.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res 47 (W1). W556–W560.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res 38 (Web Server Issue). W214–W220. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res 48 (W1). W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue
J, Wang H, Li T and Wang C: TISCH2: Expanded datasets and new tools
for single-cell transcriptome analyses of the tumor
microenvironment. Nucleic Acids Res. 51(D1): D1425–D1431. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Neal JT, Li X, Zhu J, Giangarra V,
Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et
al: Organoid modeling of the tumor immune microenvironment. Cell.
175:1972–1988.e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Borcherding N, Vishwakarma A, Voigt AP,
Bellizzi A, Kaplan J, Nepple K, Salem AK, Jenkins RW, Zakharia Y
and Zhang W: Mapping the immune environment in clear cell renal
carcinoma by single-cell genomics. Commun Biol. 4:1222021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu L, Deng C, Pang B, Zhang X, Liu W, Liao
G, Yuan H, Cheng P, Li F, Long Z, et al: TIP: A web server for
resolving tumor immunophenotype profiling. Cancer Res.
78:6575–6580. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ye S, Li S, Qin L, Zheng W, Liu B, Li X,
Ren Z, Zhao H, Hu X, Ye N and Li G: GBP2 promotes clear cell renal
cell carcinoma progression through immune infiltration and
regulation of PD-L1 expression via STAT1 signaling. Oncol Rep.
49:492023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cerbone L, Cattrini C, Vallome G, Latocca
MM, Boccardo F and Zanardi E: Combination therapy in metastatic
renal cell carcinoma: Back to the future? Semin Oncol. 47:361–366.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Braun DA, Bakouny Z, Hirsch L, Flippot R,
Van Allen EM, Wu CJ and Choueiri TK: Beyond conventional
immune-checkpoint inhibition-novel immunotherapies for renal cell
carcinoma. Nat Rev Clin Oncol. 18:199–214. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Santos JC and Broz P: Sensing of invading
pathogens by GBPs: At the crossroads between cell-autonomous and
innate immunity. J Leukoc Biol. 104:729–735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fu J, Qin W, Tong Q, Li Z, Shao Y, Liu Z,
Liu C, Wang Z and Xu X: A novel DNA methylation-driver gene
signature for long-term survival prediction of hepatitis-positive
hepatocellular carcinoma patients. Cancer Med. 11:4721–4735. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zahra A, Dong Q, Hall M, Jeyaneethi J,
Silva E, Karteris E and Sisu C: Identification of potential
bisphenol A (BPA) exposure biomarkers in ovarian cancer. J Clin
Med. 10:19792021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arner EN and Rathmell WK: Mutation and
tissue lineage lead to organ-specific cancer. Nature. 606:871–872.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu P, Ye L, Ren Y, Zhao G, Zhang Y, Lu S,
Li Q, Wu C, Bai L, Zhang Z, et al: Chemotherapy-induced phlebitis
via the GBP5/NLRP3 inflammasome axis and the therapeutic effect of
aescin. Br J Pharmacol. 180:1132–1147. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou L, Zhao H, Zhao H, Meng X, Zhao Z,
Xie H, Li J, Tang Y and Zhang Y: GBP5 exacerbates rosacea-like skin
inflammation by skewing macrophage polarization towards M1
phenotype through the NF-κB signalling pathway. J Eur Acad Dermatol
Venereol. 37:796–809. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wilkie KP and Hahnfeldt P: Tumor-immune
dynamics regulated in the microenvironment inform the transient
nature of immune-induced tumor dormancy. Cancer Res. 73:3534–3544.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Heidegger I, Pircher A and Pichler R:
Targeting the tumor microenvironment in renal cell cancer biology
and therapy. Front Oncol. 9:4902019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Najjar YG, Rayman P, Jia X, Pavicic PJ Jr,
Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, et al:
Myeloid-derived suppressor cell subset accumulation in renal cell
carcinoma parenchyma is associated with intratumoral expression of
IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 23:2346–2355. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang
Z, Lin Z, Xiong Y, Wang J, Chang Y, et al: Intratumoral
CXCL13+CD8+T cell infiltration determines
poor clinical outcomes and immunoevasive contexture in patients
with clear cell renal cell carcinoma. J Immunother Cancer.
9:e0018232021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Giraldo NA, Becht E, Pagès F, Skliris G,
Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I,
et al: Orchestration and prognostic significance of immune
checkpoints in the microenvironment of primary and metastatic renal
cell cancer. Clin Cancer Res. 21:3031–3040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Giraldo NA, Becht E, Vano Y, Petitprez F,
Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti
A, et al: Tumor-infiltrating and peripheral blood t-cell
immunophenotypes predict early relapse in localized clear cell
renal cell carcinoma. Clin Cancer Res. 23:4416–4428. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Paluskievicz CM, Cao X, Abdi R, Zheng P,
Liu Y and Bromberg JS: T Regulatory cells and priming the
suppressive tumor microenvironment. Front Immunol. 10:24532019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Braun DA, Street K, Burke KP, Cookmeyer
DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L,
Hirsch L, et al: Progressive immune dysfunction with advancing
disease stage in renal cell carcinoma. Cancer Cell. 39:632–648.e8.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pittet MJ, Michielin O and Migliorini D:
Clinical relevance of tumour-associated macrophages. Nat Rev Clin
Oncol. 19:402–421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xiang X, Wang J, Lu D and Xu X: Targeting
tumor-associated macrophages to synergize tumor immunotherapy.
Signal Transduct Target Ther. 6:752021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zheng W, Ye S, Liu B, Liu D, Yan R, Guo H,
Yu H, Hu X, Zhao H, Zhou K and Li G: Crosstalk between GBP2 and M2
macrophage promotes the ccRCC progression. Cancer Sci.
115:3570–3586. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Meirson T, Gil-Henn H and Samson AO:
Invasion and metastasis: The elusive hallmark of cancer. Oncogene.
39:2024–2026. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
